NEW YORK (GenomeWeb) – Interpace Diagnostics today announced securities purchase agreements that are anticipated to raise $4 million in gross proceeds.

The firm said it has entered into a securities purchase agreement with three undisclosed institutional investors to purchase an aggregate of 855,000 shares of common stock in a registered direct offering. In a private placement, it also has agreed to sell warrants to the same investors to purchase 855,000 shares of its common stock at $4.69 per share.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.